Lili Nsongo

Yasmeen Rahimi

Thomas Shrader

Yale Jen

Yanan Zhu

Yigal Nochomovitz

Myles Minter

Pete Stavropoulos

Whitney Ijem

Angela Qian

Ed Arce

Evan Wang

Jake Roberge

Joohwan Kim

Kuan-Hung Lin

Samantha Schaeffer

Sarah Medeiros

Seamus Fernandez

Wing Yip

- Arcturus Therapeutics Holdings Inc.'s partner, Meiji Seika Pharma Co., Ltd., received **manufacturing and marketing approval in Japan** for **KOSTAIVE® (ARCT-2301)**, a **two-dose vial self-amplifying mRNA COVID-19 vaccine**.  **[1768224_0001193805-25-001247_e664805_ex99-1.htm:0]** **[1768224_0001193805-25-001247_e664805_8k-arct.htm:1]** 
- The vaccine targets the **SARS-CoV-2 Omicron sub lineage JN.1 variant XEC** and demonstrated neutralizing antibodies against multiple circulating variants in non-clinical studies.  **[1768224_0001193805-25-001247_e664805_ex99-1.htm:0]** **[1768224_0001193805-25-001247_e664805_8k-arct.htm:1]** 
- Meiji Seika Pharma anticipates **supplying the product starting in late September 2025**.  **[1768224_0001193805-25-001247_e664805_ex99-1.htm:0]**

Arcturus Therapeutics' Partner Receives Japanese Approval for COVID-19 Vaccine

Arcturus Therapeutics Holdings (ARCT)